Drugs / Eciskafusp Alfa
Eciskafusp Alfa
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06816017 | Jun 2025 → Oct 2028 | non-invasive bladder urothelial carcinoma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 1 | NCT04303858 | May 2020 → Oct 2025 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eciskafusp Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06816017 ↗ |
| Known as | PD1-IL2v | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314982 ↗ |
| Known as | RG-6979 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314982 ↗ |
| Known as | RG6279 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314982 ↗ |
| Known as | RO-7284755 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314982 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314982 ↗ |
| Route | Intravenous | “eciskafusp alfa will be either an intravenous administration (IV)” NCT04303858 ↗ |